These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 36848199)
1. Pharmacodynamic and immunological interactions of amphotericin B formulations and voriconazole with human neutrophils against mature Scedosporium apiospermum and Fusarium spp. biofilms. Vikelouda K; Simitsopoulou M; Antachopoulos C; Skoura L; Roilides E J Antimicrob Chemother; 2023 Apr; 78(4):1076-1083. PubMed ID: 36848199 [TBL] [Abstract][Full Text] [Related]
2. Activity of Amphotericin B Formulations and Voriconazole, Alone or in Combination, against Biofilms of Vikelouda K; Simitsopoulou M; Skoura L; Antachopoulos C; Roilides E Antimicrob Agents Chemother; 2021 Oct; 65(11):e0063821. PubMed ID: 34370583 [No Abstract] [Full Text] [Related]
3. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. Gil-Lamaignere C; Roilides E; Maloukou A; Georgopoulou I; Petrikkos G; Walsh TJ J Antimicrob Chemother; 2002 Dec; 50(6):1027-30. PubMed ID: 12461027 [TBL] [Abstract][Full Text] [Related]
4. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Gil-Lamaignere C; Roilides E; Mosquera J; Maloukou A; Walsh TJ Antimicrob Agents Chemother; 2002 Jul; 46(7):2234-7. PubMed ID: 12069979 [TBL] [Abstract][Full Text] [Related]
5. Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: comparison with Aspergillus fumigatus. Dotis J; Simitsopoulou M; Dalakiouridou M; Konstantinou T; Panteliadis C; Walsh TJ; Roilides E J Antimicrob Chemother; 2008 Apr; 61(4):810-7. PubMed ID: 18272514 [TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Lewis RE; Wiederhold NP; Klepser ME Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887 [TBL] [Abstract][Full Text] [Related]
7. Decoding the antifungal resistance mechanisms in biofilms of emerging, ubiquitous and multidrug-resistant species belonging to the Scedosporium/Lomentospora genera. Mello TP; Oliveira SSC; Branquinha MH; Santos ALS Med Mycol; 2022 Jun; 60(6):. PubMed ID: 35641191 [TBL] [Abstract][Full Text] [Related]
8. Efflux pump inhibition controls growth and enhances antifungal susceptibility of A Cordeiro R; Portela FV; Pereira LM; de Andrade AR; de Sousa JK; Aguiar AL; Pergentino ML; de Sales GS; de Oliveira JS; Medrano DJ; Brilhante RS; Rocha MF; Scm Castelo-Branco D; Sidrim JJ Future Microbiol; 2020 Jan; 15():9-20. PubMed ID: 32043371 [No Abstract] [Full Text] [Related]
9. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. Johnson EM; Szekely A; Warnock DW J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species. Valentín A; Cantón E; Pemán J; Fernandez-Rivero ME; Tormo-Mas MA; Martínez JP J Antimicrob Chemother; 2016 Dec; 71(12):3449-3452. PubMed ID: 27543657 [TBL] [Abstract][Full Text] [Related]
12. Characterization of fusarium keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis. Mukherjee PK; Chandra J; Yu C; Sun Y; Pearlman E; Ghannoum MA Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4450-7. PubMed ID: 22669723 [TBL] [Abstract][Full Text] [Related]
13. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. Espinel-Ingroff A J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410 [TBL] [Abstract][Full Text] [Related]
14. Effects of interleukin-15 on antifungal responses of human polymorphonuclear leukocytes against Fusarium spp. and Scedosporium spp. Winn RM; Gil-Lamaignere C; Roilides E; Simitsopoulou M; Lyman CA; Maloukou A; Walsh TJ Cytokine; 2005 Jul; 31(1):1-8. PubMed ID: 15935692 [TBL] [Abstract][Full Text] [Related]
15. Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model. El-Azizi M; Farag N; Khardori N Ann Clin Microbiol Antimicrob; 2015 Apr; 14():21. PubMed ID: 25885806 [TBL] [Abstract][Full Text] [Related]
16. Changing epidemiology of rare mould infections: implications for therapy. Malani AN; Kauffman CA Drugs; 2007; 67(13):1803-12. PubMed ID: 17722951 [TBL] [Abstract][Full Text] [Related]
17. Activity of MSI-78, h-Lf1-11 and cecropin B antimicrobial peptides alone and in combination with voriconazole and amphotericin B against clinical isolates of Fusarium solani. Denardi LB; Weiblen C; Ianiski LB; Stibbe PC; Santurio JM J Mycol Med; 2021 Jun; 31(2):101119. PubMed ID: 33626413 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the expanding spectrum of sertraline against uncommon fungal pathogens. Villanueva-Lozano H; González GM; Espinosa-Mora JE; Bodden-Mendoza BA; Andrade A; Martínez-Reséndez MF; Treviño-Rangel RJ J Infect Chemother; 2020 Mar; 26(3):309-311. PubMed ID: 31678053 [TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101 [TBL] [Abstract][Full Text] [Related]